Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor
Molecules · 2024
DOI: 10.3390/molecules29040821 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2024. Verfasst von Filipa C Ferreira und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biosystems & Integrative Sciences Institute (BioISI), Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis, Aminopyridines, Indoles. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Foundation, Fundação para a Ciência e Tecnologia, FCT.
Abstract (Originalsprache)
The monogenic rare disease Cystic Fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance (CFTR) protein, an anion channel expressed at the apical plasma membrane of epithelial cells. The discovery and subsequent development of CFTR modulators—small molecules acting on the basic molecular defect in CF—have revolutionized the standard of care for people with CF (PwCF), thus drastically improving their clinical features, prognosis, and quality of life. Currently, four of these drugs are approved for clinical use: potentiator ivacaftor (VX-770) alone or in combination with correctors lumacaftor, (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445). Noteworthily, the triple combinatorial therapy composed of ivacaftor, tezacaftor, and elexacaftor constitutes the most effective modulator therapy nowadays for the majority of PwCF. In this review, we exploit the organic synthesis of ivacaftor, tezacaftor, and elexacaftor by providing a retrosynthetic drug analysis for these CFTR modulators. Furthermore, we describe the current understanding of the mechanisms of action (MoA’s) of these compounds by discussing several studies that report the key findings on the molecular mechanisms underlying their action on the CFTR protein.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biosystems & Integrative Sciences Institute (BioISI), Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal.
- Department of Chemistry, Pontifical Catholic University of Rio de Janeiro (PUC-Rio), Rio de Janeiro 22435-900, RJ, Brazil.
ORCID-Profile: Filipa C Ferreira, Camilla D Buarque, Miquéias Lopes-Pacheco
Förderung
- Cystic Fibrosis Foundation
- Fundação para a Ciência e Tecnologia
- FCT
- CAPES
- CNPq
- FAPERJ
Zitieren
APA
Ferreira, F. C., Buarque, C. D., & Lopes-Pacheco, M. (2024). Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor. Molecules. https://doi.org/10.3390/molecules29040821
Vancouver
Ferreira FC, Buarque CD, Lopes-Pacheco M. Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor. Molecules. 2024. doi:10.3390/molecules29040821
BibTeX
@article{Ferreira2024,
author = {Ferreira, Filipa C and Buarque, Camilla D and Lopes-Pacheco, Miquéias},
title = {Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29040821}
}
EUVIMED